Eli Lilly Transfers Bioanalytical Drug Discovery Capabilities to Advion | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Advion BioServices today said that under a new, multi-year contract it will provide drug giant Eli Lilly with drug discovery bioanalytical services

In addition, it said that Lilly will transition its drug discovery bioanalytical capability to Advion BioServices, which is a subsidiary of Advion BioSciences. All Lilly employees impacted by the transfer will have the opportunity to join Advion.

Financial terms of the transaction were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.